ZIG
BCLI

Zullo Investment Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Zullo Investment Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,074
Closed -$4.4K – 156
2023
Q4 		$4.4K Buy
+1,074
New +$3.22K ﹤0.01% 150

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Zullo Investment Group's BCLI Position: Q1 2024 in Review

Zullo Investment Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2024, closing a stake of 1,074 shares — an estimated $4.4K sold.

Zullo Investment Group first reported a position in BCLI in Q4 2023 and held it in 1 quarter. The position peaked at $4.4K in Q4 2023. 47 funds tracked by Wall St. Rank hold BCLI as of Q1 2024.

  • Zullo Investment Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2024 after selling out during the quarter.
  • Zullo Investment Group sold 1,074 BRAINSTORM CELL THERAPUTC shares in Q1 2024, an estimated $4.4K.
  • Zullo Investment Group first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2023 and held it in 1 quarter.
  • Zullo Investment Group's BRAINSTORM CELL THERAPUTC position peaked at $4.4K in Q4 2023.
  • 47 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2024.

Based on Zullo Investment Group's 13F filing for Q1 2024, filed 24 Apr 2024.